Details of the Drug
General Information of Drug (ID: DMTS1X5)
| Drug Name |
LY-2300559
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
MGlu2 Pot/Cys (migraine prevention), Eli Lilly; Metabotropic glutamate 2 receptor potentiator/cysteinyl leukotriene receptor 1 antagonist (migraine), Eli Lilly; Mglu2 potentiator/CysLT1 antagonist (migraine prevention), Eli Lilly
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 434.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.9 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 9 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Migraine | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 8A80 | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||


